U.S. Investment Arm of Tokyo Electron Invests Additional Capital into Unidym

Unidym, a majority owned subsidiary of Arrowhead Research Corporation (NASDAQ: ARWR), announced today that TEL Venture Capital, Inc., the U.S. investment arm of Tokyo Electron, has invested additional capital into the company. Concurrent with the investment, Unidym and Tokyo Electron intend to enter into a program to develop equipment for use in the production and integration of Unidym’s films. The two companies also agreed to share information to advance Unidym's progress in printed electronics, a disruptive approach to electronics manufacturing that leverages inexpensive wet coating processes rather than the more expensive processes currently employed in the electronics industry.

Unidym is a leader in carbon nanotube-based transparent, conductive films (TCFs) for the electronics industry. TCFs are a critical component in devices such as touch panels, displays, and thin-film solar cells. For example, both touch panels and LCDs typically employ two TCF layers per device. Unidym's TCFs offer substantial advantages over the incumbent technology, indium-based metal oxides, including: improved durability, lower processing costs, and lower overall cost structure. For the LCD and solar industries, Unidym plans to sell a TCF ink that customers will deposit in their manufacturing lines. TEL and Unidym intend to work together to modify TEL's existing equipment to support Unidym's inks.

"Tokyo Electron's follow on investment validates our product offering in the display industry," said Art Swift, President and CEO of Unidym. "TEL is one of the world's leading suppliers of LCD manufacturing equipment and an ideal partner to provide complete equipment solutions to our LCD display customers."

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.